**Core Concept**
The question is testing the knowledge of direct oral anticoagulants (DOACs), specifically the class of drugs that inhibit factor Xa, a crucial enzyme in the coagulation cascade. Factor Xa inhibitors prevent the conversion of prothrombin to thrombin, thereby reducing the formation of blood clots.

**Why the Correct Answer is Right**
The correct answer is a direct oral factor Xa inhibitor, which works by binding to and inhibiting free and clot-bound factor Xa. This leads to a decrease in thrombin generation and subsequent clot formation. The mechanism of action involves the inhibition of the prothrombinase complex, which is composed of factor Xa and factor Va. The direct oral factor Xa inhibitors, such as rivaroxaban, apixaban, and edoxaban, are administered orally and have a predictable and stable pharmacokinetic profile.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because it does not specify a direct oral factor Xa inhibitor.
**Option B:** This option is incorrect because it may refer to a different class of anticoagulants, such as vitamin K antagonists or heparins.
**Option C:** This option is incorrect because it may refer to a different class of anticoagulants, such as direct oral thrombin inhibitors.

**Clinical Pearl / High-Yield Fact**
The direct oral factor Xa inhibitors have a predictable and stable pharmacokinetic profile, which allows for fixed dosing without the need for regular monitoring of coagulation parameters. However, they can increase the risk of bleeding, particularly in patients with renal impairment or those taking concomitant medications that enhance bleeding risk.

**Correct Answer: A. Rivaroxaban**